If You Invested in Vigil Neuroscience, Inc. (VIGL)

Vigil Neuroscience, Inc. (VIGL) was a clinical-stage biotechnology company focused on research and development in biotechnology, specifically on treatments for neurodegenerative diseases. According to company disclosures, Vigil concentrated on restoring the vigilance of microglia, the sentinel immune cells of the brain, to address both rare and common neurodegenerative conditions. The company’s work placed it within the professional, scientific, and technical services sector, with its common stock previously listed on The Nasdaq Global Select Market under the symbol VIGL.

Vigil’s approach centered on the biology of TREM2 (triggering receptor expressed on myeloid cells 2), a receptor expressed on microglia. Across its programs, Vigil described itself as utilizing the tools of modern neuroscience drug development and multiple therapeutic modalities to develop precision-based therapies intended to improve the lives of patients and their families.

Core Programs and Scientific Focus

The company’s pipeline, as described in its public communications, was built around two main product candidates targeting TREM2:

• Iluzanebart (also referred to as VGL101): a fully human monoclonal antibody agonist of TREM2, developed for people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil reported that iluzanebart was evaluated in the global Phase 2 open-label IGNITE clinical trial and supported by the ILLUMINATE natural history study of ALSP, which was designed to better understand disease progression and biomarkers such as MRI and neurofilament light chain (NfL).
• VG-3927: a novel, orally bioavailable small molecule TREM2 agonist developed for common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD). Vigil described VG-3927 as a potent small molecule TREM2 agonist with a mode of action that includes agonism and positive allosteric modulation, designed to enhance protective microglial responses to aggregated amyloid and tau without increasing inflammation.

Vigil characterized itself as a clinical-stage company. It reported that iluzanebart had been advanced into a Phase 2 trial in ALSP, while VG-3927 had completed a Phase 1 single and multiple ascending dose trial assessing safety, tolerability, pharmacokinetics, and pharmacodynamics, including cohorts of healthy volunteers, elderly participants, and Alzheimer’s disease patients.

Microglia and Neurodegenerative Disease

In its public statements, Vigil emphasized the role of microglia in neurodegenerative diseases. The company noted that in conditions such as Alzheimer’s disease, microglial activation can become dysregulated, leading to debris accumulation, chronic inflammation, and neurodegeneration in the central nervous system. By activating TREM2, Vigil aimed to enhance the neuroprotective functions of microglia, including migration to sites of injury, phagocytosis, proliferation, and survival.

For ALSP, Vigil highlighted that the disease is caused by mutations in the CSF1R gene and is characterized by cognitive dysfunction, neuropsychiatric symptoms, and motor impairment, with rapid progression and significant patient and caregiver burden. The company noted that there were no approved therapies for ALSP, underscoring the unmet medical need that iluzanebart was intended to address.

Acquisition by Sanofi and Trading Status

Vigil Neuroscience’s status as an independent public company changed following its acquisition by Sanofi. According to a Form 8-K filed with the U.S. Securities and Exchange Commission (SEC), on August 5, 2025, Sanofi completed the previously announced acquisition of Vigil Neuroscience, Inc. through a merger in which a wholly owned Sanofi subsidiary merged with and into Vigil, with Vigil surviving as a wholly owned subsidiary of Sanofi. As a result of the merger, each issued and outstanding share of Vigil common stock (subject to specified exceptions) was converted into the right to receive a cash payment and a contingent value right (CVR) tied to the first commercial sale of VG-3927, as described in the merger documentation.

In connection with the completion of the merger, Vigil notified The Nasdaq Stock Market LLC of the transaction and requested the filing of a Form 25 to remove its common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. A Form 25 (25-NSE) was subsequently filed, identifying Vigil Neuroscience, Inc. as the issuer and Nasdaq Stock Market LLC as the exchange, and specifying the removal of its common stock from listing. Following this, Vigil filed a Form 15 to terminate the registration of its common stock under Section 12(g) of the Exchange Act and to suspend its reporting obligations under Sections 13 and 15(d). The Form 15 indicated an approximate number of one holder of record as of the certification date.

As a result of these steps, Vigil Neuroscience’s common stock is no longer listed on Nasdaq, and the company has suspended its periodic reporting obligations as a standalone registrant. Vigil continues as a wholly owned subsidiary of Sanofi rather than as an independent publicly traded entity.

Clinical Development and Research Activities

Vigil’s disclosures describe a development strategy focused on:

• Conducting clinical trials in rare neurodegenerative disease (ALSP) through the IGNITE Phase 2 trial and the ILLUMINATE natural history study, which was characterized as the first natural history study in ALSP designed to better understand the disease and inform clinical development.
• Advancing VG-3927 through early-stage clinical evaluation, including Phase 1 trials that assessed safety, tolerability, pharmacokinetics, and pharmacodynamics in multiple cohorts, and preclinical work demonstrating brain penetration, TREM2 engagement, and modulation of microglial activity in models of amyloid and tau pathology.
• Presenting scientific and clinical data at neurology and neurodegeneration-focused conferences, such as the AD/PD™ International Conference on Alzheimer’s and Parkinson’s Diseases and other scientific meetings, to share findings on TREM2 agonism and microglial biology.

Across these activities, Vigil positioned its TREM2 agonist programs as potential next-generation approaches that could complement or go beyond existing amyloid-based strategies in Alzheimer’s disease by targeting additional contributors to disease progression.

Regulatory and Corporate Milestones

Public filings and press releases describe several notable milestones for Vigil Neuroscience:

• Regulatory interactions, including a Type C meeting with the U.S. Food and Drug Administration (FDA) in which the agency stated it was open to considering an accelerated approval pathway for iluzanebart in ALSP, as reported by the company.
• Completion of enrollment in the IGNITE Phase 2 trial and expansion of the ILLUMINATE natural history study, which provided data on biomarkers and disease progression in ALSP.
• A strategic equity investment by Sanofi prior to the acquisition, which included a right of first negotiation for an exclusive license or transfer of rights to Vigil’s small molecule TREM2 agonist program, including VG-3927, as described in company communications summarizing 2024 achievements.
• The subsequent definitive merger agreement and completed acquisition by Sanofi, leading to a change in control and the delisting and deregistration of Vigil’s common stock.

Position Within the Biotechnology Landscape

Within the broader biotechnology sector, Vigil Neuroscience described itself as a company focused on microglia and TREM2 biology, with programs spanning a rare, genetically defined neurodegenerative disease (ALSP) and a prevalent condition (Alzheimer’s disease). Its work was situated at the intersection of neuroimmunology and neurodegeneration, using monoclonal antibody and small molecule approaches to modulate microglial function.

Following the completion of the merger with Sanofi and the subsequent delisting and deregistration of its common stock, Vigil’s activities and programs, including VG-3927, are part of Sanofi’s neurology-focused research and development efforts as described in the merger-related disclosures.

FAQ